A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS). It is hypothesised that PYM50028 will be safe and well tolerated in this study and demonstrate therapeutic benefit in this patient population.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
425
Unified Parkinson's Disease Rating Scale parts II & III combined score
Time frame: 28 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mayo Clinic
Scottsdale, Arizona, United States
University of California, Irvine
Irvine, California, United States
Coastal Neurological Medical Group
La Jolla, California, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Pacific Neuroscience
Oxnard, California, United States
Ellison Ambulatory Care Center
Sacramento, California, United States
The Parkinson's Institute
Sunnyvale, California, United States
Colorado Neurological Institute, Rocky Mountain Movement Disorders Center
Englewood, Colorado, United States
Hartford Hospital
Manchester, Connecticut, United States
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States
...and 101 more locations